{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T05:09:36Z","timestamp":1781154576121,"version":"3.54.1"},"reference-count":15,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2019,10,21]],"date-time":"2019-10-21T00:00:00Z","timestamp":1571616000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Background and Objectives: Tadalafil for treatment of fetal growth restriction (FGR) or preeclampsia is given once a day orally. The drug kinetics of tadalafil were investigated to determine the ideal dosage to promote uterine blood flow. Materials and Methods: We recruited five pregnant women with FGR or preeclampsia before administration of tadalafil, all of which were administered tadalafil (20 mg\/day, once-daily dosing). The blood concentration of tadalafil was measured 1, 2, 4, 6, 8, and 24 h after administration, and uterine blood flow was measured before tadalafil administration and 2\u20134 and 20\u201324 h after. We then analyzed the correlation between tadalafil blood concentration and uterine artery blood flow. Results: The blood concentration of tadalafil correlated with uterine artery blood flow in pregnant women. The blood concentration of tadalafil and uterine artery blood flow decreased 5 h after administration of tadalafil. Conclusions: The blood concentration of tadalafil and uterine artery blood flow fluctuate in parallel, the latter was decreased by reduced blood concentration. Thus, a study of tadalafil administered twice a day in pregnant women will be needed to stabilize uterine artery blood flow.<\/jats:p>","DOI":"10.3390\/medicina55100708","type":"journal-article","created":{"date-parts":[[2019,10,21]],"date-time":"2019-10-21T11:37:55Z","timestamp":1571657875000},"page":"708","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Maternal Blood Concentration of Tadalafil and Uterine Blood Flow in Pregnancy"],"prefix":"10.3390","volume":"55","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1760-691X","authenticated-orcid":false,"given":"Hiroaki","family":"Tanaka","sequence":"first","affiliation":[{"name":"Department of Obstetrics and Gynecology, Mie University School of Medicine, 2-174 Edobashi, Tsu, Mie 514-8507, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shintaro","family":"Maki","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Mie University School of Medicine, 2-174 Edobashi, Tsu, Mie 514-8507, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9322-135X","authenticated-orcid":false,"given":"Shoichi","family":"Magawa","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Mie University School of Medicine, 2-174 Edobashi, Tsu, Mie 514-8507, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masafumi","family":"Nii","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Mie University School of Medicine, 2-174 Edobashi, Tsu, Mie 514-8507, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8373-1567","authenticated-orcid":false,"given":"Kayo","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Mie University School of Medicine, 2-174 Edobashi, Tsu, Mie 514-8507, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1870-9571","authenticated-orcid":false,"given":"Kenji","family":"Ikemura","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy and Biopharmaceutics, Mie University Hospital, 2-174 Edobashi, Tsu, Mie 514-8507, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9372-1808","authenticated-orcid":false,"given":"Kuniaki","family":"Toriyabe","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Mie University School of Medicine, 2-174 Edobashi, Tsu, Mie 514-8507, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoaki","family":"Ikeda","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Mie University School of Medicine, 2-174 Edobashi, Tsu, Mie 514-8507, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2019,10,21]]},"reference":[{"key":"ref_1","unstructured":"American College of Obstetricians and Gynecologists (2013). ACOG Practice bulletin no. 134 fetal growth restriction. Obstet. Gynecol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.bpobgyn.2007.06.004","article-title":"Diagnosis and management of fetal growth restriction: The role of fetal therapy","volume":"22","author":"Hui","year":"2008","journal-title":"Best Pract. Res. Clin. Obstet. Gynaecol."},{"key":"ref_3","first-page":"1","article-title":"Cardiac function and tadalafil used for treating fetal growth restriction in pregnant women without cardiovascular disease","volume":"20","author":"Tanaka","year":"2018","journal-title":"J. Matern.-Fetal Neonatal Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1093\/ajh\/hpx130","article-title":"Tadalafil improves L-NG-nitroarginine methyl Ester-Induced preeclampsia with fetal growth Restriction-Like symptoms in pregnant mice","volume":"31","author":"Yoshikawa","year":"2017","journal-title":"Am. J. Hypertens."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1111\/jog.13345","article-title":"Safety and dose-finding trial of tadalafil administered for fetal growth restriction: A Phase-1 clinical study","volume":"43","author":"Kubo","year":"2017","journal-title":"J. Obstet. Gynaecol. Res."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1111\/jog.13335","article-title":"Treatment using tadalafil for severe pre-eclampsia with fetal growth restriction","volume":"43","author":"Tanaka","year":"2017","journal-title":"J. Obstet. Gynaecol. Res."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1111\/jog.13218","article-title":"Retrospective study of tadalafil for fetal growth restriction: Impact on maternal and perinatal outcomes","volume":"43","author":"Kubo","year":"2017","journal-title":"J. Obstet. Gynaecol. Res."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"935","DOI":"10.2147\/DDDT.S155040","article-title":"Comparison of tadalafil pharmacokinetics after administration of a new orodispersible film versus a film-coated tablet","volume":"12","author":"Park","year":"2018","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1111\/j.1742-1241.2006.01049.x","article-title":"Comparison of phosphodiesterase type 5 (PDE5) inhibitors","volume":"60","author":"Wright","year":"2006","journal-title":"Int. J. Clin. Pract."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e020948","DOI":"10.1136\/bmjopen-2017-020948","article-title":"TADAFER study group. TADAFER II: Tadalafil treatment for fetal growth restriction\u2014A study protocol for a multicenter randomised controlled phase II trial","volume":"8","author":"Umekawa","year":"2018","journal-title":"BMJ Open"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Maki, S., Tanaka, H., Tsuji, M., Furuhashi, F., Magawa, S., Kaneda, M.K., Nii, M., Tanaka, K., Kondo, E., and Tamaru, S. (2019). Safety Evaluation of Tadalafil Treatment for Fetuses with Early-Onset Growth Restriction (TADAFER): Results from the Phase II Trial. J. Clin. Med., 15.","DOI":"10.3390\/jcm8060856"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S2352-4642(17)30173-6","article-title":"Maternal sildenafil for severe fetal growth restriction (STRIDER): A multicentre, randomised, placebo-controlled, Double-Blind trial","volume":"2","author":"Sharp","year":"2018","journal-title":"Lancet Child Adolesc. Health"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/978-1-60327-325-1_15","article-title":"Reverse-phase High-Performance liquid chromatography (HPLC) analysis of retinol and retinyl esters in mouse serum and tissues","volume":"652","author":"Kim","year":"2010","journal-title":"Methods Mol. Biol."},{"key":"ref_14","first-page":"78","article-title":"Improved prediction of Pre-Eclampsia by Two-Stage screening of uterine arteries using the early diastolic notch and color Doppler imaging","volume":"82","author":"Bower","year":"1993","journal-title":"Obstet. Gynecol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1067\/mob.2001.117187","article-title":"A longitudinal study of quantitative uterine blood flow with the use of color power angiography in appropriate for gestational age pregnancies","volume":"185","author":"Konje","year":"2001","journal-title":"Am. J. Obstet. Gynecol."}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/55\/10\/708\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T13:28:11Z","timestamp":1760189291000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/55\/10\/708"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,21]]},"references-count":15,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2019,10]]}},"alternative-id":["medicina55100708"],"URL":"https:\/\/doi.org\/10.3390\/medicina55100708","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,21]]}}}